Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery
- PMID: 26497796
- DOI: 10.1016/bs.pbr.2015.04.014
Rho kinase inhibitor AMA0526 improves surgical outcome in a rabbit model of glaucoma filtration surgery
Abstract
Purpose: First, to elucidate the effect of Rho kinase inhibitor, AMA0526, on Human Tenon Fibroblast (HTF) proliferation and transdifferentiation to myofibroblasts. Second, the effects of ROCK inhibition on the wound healing process and surgical outcome were investigated in a rabbit model of glaucoma filtration surgery.
Methods: After exposure of HTF to AMA0526 (0.1-25 μM), a water-soluble tetrazolium salt-1 assay and caspase 3/7 activity assay were used to assess its effect on cell proliferation and to elucidate any toxic effects, respectively. Immunohistochemistry of α-smooth muscle actin expression was used to investigate fibroblast-to-myofibroblast differentiation induced by transforming growth factor-beta 1 (TGF-β1) in the presence or absence of the ROCK inhibitor. The effect of topical treatment was studied in a rabbit model of glaucoma filtration surgery. Treatment outcome was studied by performing intraocular pressure (IOP) measurements and clinical investigation of the bleb area and survival. Immunohistological analysis for inflammation (CD45), angiogenesis (CD31), and collagen I was performed at day 8, 14, and 30 after surgery (n=5/time point). Separate control groups treated with vehicle were used as control.
Results: In vitro results showed that AMA0526 dose dependently inhibited proliferation of HTF (P<0.05) without the induction of caspase 3/7 activity. Incubation of HTF with the AMA0526 inhibited TGF-β1 induced fibroblast-to-myofibroblast differentiation. In the rabbit model, topical treatment significantly improved surgical outcome. Compared to vehicle-treated eyes, AMA0526 resulted in increased bleb area (P<0.0001) and prolonged survival (P=0.0025). IOP remained significantly lower throughout the course of the experiment in the AMA0526 group (P<0.0001). Histological evaluation revealed that blebs treated with the ROCK inhibitor were characterized by reduced inflammation, angiogenesis, and collagen deposition at the site of filtration surgery (P<0.05).
Conclusions: AMA0526 had profound effects on HTF proliferation and myofibroblast transition and improved glaucoma filtration surgery outcome by interfering at different levels of the wound healing process. Therefore, these data indicate that ROCK inhibitors may be considered as more physiological agents which specifically target the wound healing process to improve the outcome of glaucoma surgery.
Keywords: Fibrosis; Glaucoma filtration surgery; Rho kinase inhibitors; Wound healing.
© 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery.Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549-57. doi: 10.1167/iovs.07-0878. Invest Ophthalmol Vis Sci. 2007. PMID: 18055804
-
Inhibition of Rho-Associated Kinase Prevents Pathological Wound Healing and Neovascularization After Corneal Trauma.Cornea. 2015 Sep;34(9):1120-9. doi: 10.1097/ICO.0000000000000493. Cornea. 2015. PMID: 26075454
-
The role of different VEGF isoforms in scar formation after glaucoma filtration surgery.Exp Eye Res. 2011 Nov;93(5):689-99. doi: 10.1016/j.exer.2011.08.016. Epub 2011 Sep 1. Exp Eye Res. 2011. PMID: 21907194
-
[The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma].Nippon Ganka Gakkai Zasshi. 2009 Nov;113(11):1071-81. Nippon Ganka Gakkai Zasshi. 2009. PMID: 19994585 Review. Japanese.
-
Modulation of wound healing in glaucoma surgery.Prog Brain Res. 2015;221:319-40. doi: 10.1016/bs.pbr.2015.05.002. Epub 2015 Jun 30. Prog Brain Res. 2015. PMID: 26518085 Review.
Cited by
-
Involvement of Rho-associated coiled-coil kinase signaling inhibition in TGF-β1/Smad2, 3 signal transduction in vitro.Int J Ophthalmol. 2017 Dec 18;10(12):1805-1811. doi: 10.18240/ijo.2017.12.03. eCollection 2017. Int J Ophthalmol. 2017. PMID: 29259896 Free PMC article.
-
Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.Int Ophthalmol. 2022 Jan;42(1):281-294. doi: 10.1007/s10792-021-02002-w. Epub 2021 Aug 27. Int Ophthalmol. 2022. PMID: 34453229 Review.
-
The Mechanisms of Neuroprotection by Topical Rho Kinase Inhibition in Experimental Mouse Glaucoma and Optic Neuropathy.Invest Ophthalmol Vis Sci. 2024 Nov 4;65(13):43. doi: 10.1167/iovs.65.13.43. Invest Ophthalmol Vis Sci. 2024. PMID: 39565302 Free PMC article.
-
Netarsudil as an Adjunctive Therapy: Efficacy and Factors Contributing to a Favorable IOP-Lowering Effect.J Ophthalmol. 2022 Dec 30;2022:6925027. doi: 10.1155/2022/6925027. eCollection 2022. J Ophthalmol. 2022. PMID: 36620524 Free PMC article.
-
Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy.Ophthalmol Ther. 2023 Dec;12(6):2943-2957. doi: 10.1007/s40123-023-00820-y. Epub 2023 Oct 14. Ophthalmol Ther. 2023. PMID: 37837578 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous